By Fineline Cube 
Johnson & Johnson (J&J, NYSE: JNJ) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has approved a Type II variation to the label of Darzalex® (daratumumab) subcutaneous (SC) formulation, enabling patients with multiple myeloma—or their trained caregivers—to self-administer the therapy starting from the fifth dose. This landmark decision makes Darzalex SC the first oncology injectable in Europe authorized for at-home self-use, marking a major advance in treatment convenience and patient autonomy for a chronic blood cancer requiring long-term therapy.
Regulatory Update Summary
| Approval Detail | Description |
|---|---|
| Agency | EMA CHMP |
| Product | Darzalex (daratumumab) SC |
| Indication | Multiple myeloma |
| New Authorization | Self-administration from Dose 5 onward |
| Conditions | – Healthcare professional deems appropriate – Patient/caregiver completes proper training |
| Significance | First oncology injectable in Europe approved for self-administration |
The change builds on Darzalex SC’s existing approval as the only CD38-targeting antibody available in subcutaneous form for multiple myeloma.
Technology Enabling Self-Administration
- Platform: Halozyme’s ENHANZE® drug delivery technology
- Key Component: Recombinant human hyaluronidase PH20 (rHuPH20)
- Function: Temporarily degrades hyaluronan in subcutaneous tissue, enabling rapid dispersion and absorption of large-volume biologics
- Dosing Advantage: Reduces administration time from hours (IV) to 3–5 minutes (SC), now extendable to home setting
This technology has been pivotal in transforming Darzalex from a clinic-dependent infusion to a patient-centric therapy.
Clinical & Quality-of-Life Impact
- Treatment Burden Reduction: Eliminates need for frequent hospital or infusion center visits after initial doses
- Continuity of Care: Supports uninterrupted therapy during travel, pandemics, or rural access challenges
- Patient Empowerment: Aligns with growing demand for decentralized and home-based cancer care models
J&J noted that clinical trials demonstrated comparable efficacy and safety between SC and IV formulations, with no new risks identified in outpatient or self-administered settings.
Market Implications
- Competitive Edge: Reinforces Darzalex’s leadership in multiple myeloma—global sales exceeded $7 billion in 2025
- Differentiation: No other oncology biologic in Europe offers approved self-injection, creating a unique value proposition
- Payer Appeal: Potential to reduce healthcare system costs via lower administration fees and facility utilization
The update is expected to accelerate adoption in community oncology practices and support earlier-line use in newly diagnosed patients.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory implementation, market adoption, and patient access. Actual outcomes may vary due to national reimbursement decisions, training program rollout, and real-world adherence.-Fineline Info & Tech